High-throughput screening for modulators of ACVR1 transcription

Discovery of potential therapeutics for fibrodysplasia ossificans progressiva

Serena Cappato, Laura Tonachini, Francesca Giacopelli, Mario Tirone, Luis Juan V Galietta, Martina Sormani, Anna Giovenzana, Antonello Spinelli, Barbara Canciani, Silvia Brunelli, Roberto Ravazzolo, Renata Bocciardi

Research output: Contribution to journalArticle

Abstract

The ACVR1 gene encodes a type I receptor of bone morphogenetic proteins (BMPs). Activating mutations in ACVR1 are responsible for fibrodysplasia ossificans progressiva (FOP), a rare disease characterized by congenital toe malformation and progressive heterotopic endochondral ossification leading to severe and cumulative disability. Until now, no therapy has been available to prevent soft-tissue swelling (flare-ups) that trigger the ossification process. With the aim of finding a new therapeutic strategy for FOP, we developed a high-throughput screening (HTS) assay to identify inhibitors of ACVR1 gene expression among drugs already approved for the therapy of other diseases. The screening, based on an ACVR1 promoter assay, was followed by an in vitro and in vivo test to validate and characterize candidate molecules. Among compounds that modulate the ACVR1 promoter activity, we selected the one showing the highest inhibitory effect, dipyridamole, a drug that is currently used as a platelet antiaggregant. The inhibitory effect was detectable on ACVR1 gene expression, on the whole Smad-dependent BMP signaling pathway, and on chondrogenic and osteogenic differentiation processes by in vitro cellular assays. Moreover, dipyridamole reduced the process of heterotopic bone formation in vivo. Our drug repositioning strategy has led to the identification of dipyridamole as a possible therapeutic tool for the treatment of FOP. Furthermore, our study has also defined a pipeline of assays that will be useful for the evaluation of other pharmacological inhibitors of heterotopic ossification.

Original languageEnglish
Pages (from-to)685-696
Number of pages12
JournalDMM Disease Models and Mechanisms
Volume9
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Myositis Ossificans
Transcription
Modulators
Dipyridamole
Assays
Screening
Throughput
Osteogenesis
Heterotopic Ossification
Gene expression
Type I Bone Morphogenetic Protein Receptors
Drug Repositioning
Pharmaceutical Preparations
High-Throughput Screening Assays
Gene Expression
Bone Morphogenetic Proteins
Platelet Aggregation Inhibitors
Toes
Therapeutics
Rare Diseases

Keywords

  • ACVR1
  • BMP signaling pathway
  • Dipyridamole
  • Drug repositioning
  • FOP
  • High-throughput screening
  • Transcriptional regulation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine (miscellaneous)
  • Immunology and Microbiology (miscellaneous)
  • Neuroscience (miscellaneous)

Cite this

High-throughput screening for modulators of ACVR1 transcription : Discovery of potential therapeutics for fibrodysplasia ossificans progressiva. / Cappato, Serena; Tonachini, Laura; Giacopelli, Francesca; Tirone, Mario; Galietta, Luis Juan V; Sormani, Martina; Giovenzana, Anna; Spinelli, Antonello; Canciani, Barbara; Brunelli, Silvia; Ravazzolo, Roberto; Bocciardi, Renata.

In: DMM Disease Models and Mechanisms, Vol. 9, No. 6, 01.06.2016, p. 685-696.

Research output: Contribution to journalArticle

Cappato, Serena ; Tonachini, Laura ; Giacopelli, Francesca ; Tirone, Mario ; Galietta, Luis Juan V ; Sormani, Martina ; Giovenzana, Anna ; Spinelli, Antonello ; Canciani, Barbara ; Brunelli, Silvia ; Ravazzolo, Roberto ; Bocciardi, Renata. / High-throughput screening for modulators of ACVR1 transcription : Discovery of potential therapeutics for fibrodysplasia ossificans progressiva. In: DMM Disease Models and Mechanisms. 2016 ; Vol. 9, No. 6. pp. 685-696.
@article{97414b3aaa7240deb4e12a6155529bf3,
title = "High-throughput screening for modulators of ACVR1 transcription: Discovery of potential therapeutics for fibrodysplasia ossificans progressiva",
abstract = "The ACVR1 gene encodes a type I receptor of bone morphogenetic proteins (BMPs). Activating mutations in ACVR1 are responsible for fibrodysplasia ossificans progressiva (FOP), a rare disease characterized by congenital toe malformation and progressive heterotopic endochondral ossification leading to severe and cumulative disability. Until now, no therapy has been available to prevent soft-tissue swelling (flare-ups) that trigger the ossification process. With the aim of finding a new therapeutic strategy for FOP, we developed a high-throughput screening (HTS) assay to identify inhibitors of ACVR1 gene expression among drugs already approved for the therapy of other diseases. The screening, based on an ACVR1 promoter assay, was followed by an in vitro and in vivo test to validate and characterize candidate molecules. Among compounds that modulate the ACVR1 promoter activity, we selected the one showing the highest inhibitory effect, dipyridamole, a drug that is currently used as a platelet antiaggregant. The inhibitory effect was detectable on ACVR1 gene expression, on the whole Smad-dependent BMP signaling pathway, and on chondrogenic and osteogenic differentiation processes by in vitro cellular assays. Moreover, dipyridamole reduced the process of heterotopic bone formation in vivo. Our drug repositioning strategy has led to the identification of dipyridamole as a possible therapeutic tool for the treatment of FOP. Furthermore, our study has also defined a pipeline of assays that will be useful for the evaluation of other pharmacological inhibitors of heterotopic ossification.",
keywords = "ACVR1, BMP signaling pathway, Dipyridamole, Drug repositioning, FOP, High-throughput screening, Transcriptional regulation",
author = "Serena Cappato and Laura Tonachini and Francesca Giacopelli and Mario Tirone and Galietta, {Luis Juan V} and Martina Sormani and Anna Giovenzana and Antonello Spinelli and Barbara Canciani and Silvia Brunelli and Roberto Ravazzolo and Renata Bocciardi",
year = "2016",
month = "6",
day = "1",
doi = "10.1242/dmm.023929",
language = "English",
volume = "9",
pages = "685--696",
journal = "DMM Disease Models and Mechanisms",
issn = "1754-8403",
publisher = "Company of Biologists Ltd",
number = "6",

}

TY - JOUR

T1 - High-throughput screening for modulators of ACVR1 transcription

T2 - Discovery of potential therapeutics for fibrodysplasia ossificans progressiva

AU - Cappato, Serena

AU - Tonachini, Laura

AU - Giacopelli, Francesca

AU - Tirone, Mario

AU - Galietta, Luis Juan V

AU - Sormani, Martina

AU - Giovenzana, Anna

AU - Spinelli, Antonello

AU - Canciani, Barbara

AU - Brunelli, Silvia

AU - Ravazzolo, Roberto

AU - Bocciardi, Renata

PY - 2016/6/1

Y1 - 2016/6/1

N2 - The ACVR1 gene encodes a type I receptor of bone morphogenetic proteins (BMPs). Activating mutations in ACVR1 are responsible for fibrodysplasia ossificans progressiva (FOP), a rare disease characterized by congenital toe malformation and progressive heterotopic endochondral ossification leading to severe and cumulative disability. Until now, no therapy has been available to prevent soft-tissue swelling (flare-ups) that trigger the ossification process. With the aim of finding a new therapeutic strategy for FOP, we developed a high-throughput screening (HTS) assay to identify inhibitors of ACVR1 gene expression among drugs already approved for the therapy of other diseases. The screening, based on an ACVR1 promoter assay, was followed by an in vitro and in vivo test to validate and characterize candidate molecules. Among compounds that modulate the ACVR1 promoter activity, we selected the one showing the highest inhibitory effect, dipyridamole, a drug that is currently used as a platelet antiaggregant. The inhibitory effect was detectable on ACVR1 gene expression, on the whole Smad-dependent BMP signaling pathway, and on chondrogenic and osteogenic differentiation processes by in vitro cellular assays. Moreover, dipyridamole reduced the process of heterotopic bone formation in vivo. Our drug repositioning strategy has led to the identification of dipyridamole as a possible therapeutic tool for the treatment of FOP. Furthermore, our study has also defined a pipeline of assays that will be useful for the evaluation of other pharmacological inhibitors of heterotopic ossification.

AB - The ACVR1 gene encodes a type I receptor of bone morphogenetic proteins (BMPs). Activating mutations in ACVR1 are responsible for fibrodysplasia ossificans progressiva (FOP), a rare disease characterized by congenital toe malformation and progressive heterotopic endochondral ossification leading to severe and cumulative disability. Until now, no therapy has been available to prevent soft-tissue swelling (flare-ups) that trigger the ossification process. With the aim of finding a new therapeutic strategy for FOP, we developed a high-throughput screening (HTS) assay to identify inhibitors of ACVR1 gene expression among drugs already approved for the therapy of other diseases. The screening, based on an ACVR1 promoter assay, was followed by an in vitro and in vivo test to validate and characterize candidate molecules. Among compounds that modulate the ACVR1 promoter activity, we selected the one showing the highest inhibitory effect, dipyridamole, a drug that is currently used as a platelet antiaggregant. The inhibitory effect was detectable on ACVR1 gene expression, on the whole Smad-dependent BMP signaling pathway, and on chondrogenic and osteogenic differentiation processes by in vitro cellular assays. Moreover, dipyridamole reduced the process of heterotopic bone formation in vivo. Our drug repositioning strategy has led to the identification of dipyridamole as a possible therapeutic tool for the treatment of FOP. Furthermore, our study has also defined a pipeline of assays that will be useful for the evaluation of other pharmacological inhibitors of heterotopic ossification.

KW - ACVR1

KW - BMP signaling pathway

KW - Dipyridamole

KW - Drug repositioning

KW - FOP

KW - High-throughput screening

KW - Transcriptional regulation

UR - http://www.scopus.com/inward/record.url?scp=84971442590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971442590&partnerID=8YFLogxK

U2 - 10.1242/dmm.023929

DO - 10.1242/dmm.023929

M3 - Article

VL - 9

SP - 685

EP - 696

JO - DMM Disease Models and Mechanisms

JF - DMM Disease Models and Mechanisms

SN - 1754-8403

IS - 6

ER -